Tags

Type your tag names separated by a space and hit enter

A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
Clin Microbiol Infect. 2005 Sep; 11(9):736-43.CM

Abstract

An open, prospective, randomised study was conducted to compare the safety and efficacy of valacyclovir vs. oral ganciclovir for cytomegalovirus (CMV) prophylaxis in renal transplant recipients. Eighty-three renal transplant recipients were assigned randomly to receive valacyclovir (n=43) or oral ganciclovir (n=40) for the first 3 months after transplantation. Both groups were similar in terms of demographics, primary renal disease, graft source, HLA matching, immunosuppressive therapy and donor-recipient CMV antibody status. CMV infection was diagnosed by detection of virus DNA in plasma with the Amplicor CMV Test. CMV disease was observed in only one patient belonging to the ganciclovir group, who developed enterocolitis 6 months post-transplantation. No difference was observed between the two treatment groups with respect to detection of CMV DNA, virus infections other than CMV, acute rejection episodes, and serum creatinine levels at 3 and 6 months following transplantation. An increased number of bacterial infections was noted in the ganciclovir group (p 0.003). No adverse reactions with either treatment were reported. The estimated cost of valacyclovir treatment was 20% higher than that of ganciclovir treatment. Overall, both valacyclovir and oral ganciclovir were found to be effective and safe for CMV prophylaxis in renal transplant recipients. Decisions regarding prophylactic regimens should include additional criteria, such as cost or possible development of resistance.

Authors+Show Affiliations

First Department of Paediatrics, Athens University, and Transplantation Cenre, Laiko General Hospital, First Department of Propedeutic Medicine, Athens, Greece. idpavlop@yahoo.grNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16104989

Citation

Pavlopoulou, I D., et al. "A Comparative Randomised Study of Valacyclovir Vs. Oral Ganciclovir for Cytomegalovirus Prophylaxis in Renal Transplant Recipients." Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 11, no. 9, 2005, pp. 736-43.
Pavlopoulou ID, Syriopoulou VP, Chelioti H, et al. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Clin Microbiol Infect. 2005;11(9):736-43.
Pavlopoulou, I. D., Syriopoulou, V. P., Chelioti, H., Daikos, G. L., Stamatiades, D., Kostakis, A., & Boletis, J. N. (2005). A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 11(9), 736-43.
Pavlopoulou ID, et al. A Comparative Randomised Study of Valacyclovir Vs. Oral Ganciclovir for Cytomegalovirus Prophylaxis in Renal Transplant Recipients. Clin Microbiol Infect. 2005;11(9):736-43. PubMed PMID: 16104989.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. AU - Pavlopoulou,I D, AU - Syriopoulou,V Ph, AU - Chelioti,H, AU - Daikos,G L, AU - Stamatiades,D, AU - Kostakis,A, AU - Boletis,J N, PY - 2005/8/18/pubmed PY - 2005/10/13/medline PY - 2005/8/18/entrez SP - 736 EP - 43 JF - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JO - Clin Microbiol Infect VL - 11 IS - 9 N2 - An open, prospective, randomised study was conducted to compare the safety and efficacy of valacyclovir vs. oral ganciclovir for cytomegalovirus (CMV) prophylaxis in renal transplant recipients. Eighty-three renal transplant recipients were assigned randomly to receive valacyclovir (n=43) or oral ganciclovir (n=40) for the first 3 months after transplantation. Both groups were similar in terms of demographics, primary renal disease, graft source, HLA matching, immunosuppressive therapy and donor-recipient CMV antibody status. CMV infection was diagnosed by detection of virus DNA in plasma with the Amplicor CMV Test. CMV disease was observed in only one patient belonging to the ganciclovir group, who developed enterocolitis 6 months post-transplantation. No difference was observed between the two treatment groups with respect to detection of CMV DNA, virus infections other than CMV, acute rejection episodes, and serum creatinine levels at 3 and 6 months following transplantation. An increased number of bacterial infections was noted in the ganciclovir group (p 0.003). No adverse reactions with either treatment were reported. The estimated cost of valacyclovir treatment was 20% higher than that of ganciclovir treatment. Overall, both valacyclovir and oral ganciclovir were found to be effective and safe for CMV prophylaxis in renal transplant recipients. Decisions regarding prophylactic regimens should include additional criteria, such as cost or possible development of resistance. SN - 1198-743X UR - https://www.unboundmedicine.com/medline/citation/16104989/A_comparative_randomised_study_of_valacyclovir_vs__oral_ganciclovir_for_cytomegalovirus_prophylaxis_in_renal_transplant_recipients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1198-743X(14)62380-6 DB - PRIME DP - Unbound Medicine ER -